J

Johnson & Johnson

Makes prescription drugs and medical devices

Inside & Virtual Sales Specialist - Wound Closure & Healing

Full-TimePosted on 10/20/2026Deadline 11/3/26
No salary listed
Mid
Remote in UK
RemoteFully remote; occasional travel may be required for training meetings.
Sales & Account ManagementSales Development Representative, Account Management

About the job

Requirements
  • Knowledge of the MedTech environment.
  • Demonstrated ability to generate leads and nurture client relationships.
  • Experience in medical device sales; experience within Wound Closure is preferred, and full product and sales training will be provided.
  • Experience selling virtually is strongly preferred.
  • Experience using customer relationship management software to guide customers through the end-to-end customer journey.
  • Commercial acumen.
  • Influencing and business partnering skills, including the ability to understand stakeholder requirements and identify opportunities.
  • Ability to build trust with customers by asking probing questions to help them achieve their objectives and by acting in a consultative manner.
  • Ability to maintain clinical expertise in procedure and product knowledge.
  • Willingness to attend training meetings as required, which may require occasional travel.
  • Required skills include collaboration, organizing, problem solving, sales, and technical credibility.
Responsibilities
  • Conduct outbound calls and emails to prospective Wound Closure customers to arrange trial opportunities for the field-based team.
  • Research and identify potential leads through customer relationship management systems, social media, industry events, and professional networks.
  • Qualify leads against established criteria and deliver them to the sales team for face-to-face engagement and trials.
  • Maintain accurate and up-to-date records of leads, contacts, and sales activities in the customer relationship management system.
  • Collaborate with the marketing team to create and implement lead generation campaigns.
  • Achieve objectives and sales targets established in the annual performance cycle.
  • Work across the allocated customer base, remotely interacting with and promoting products to key customers and stakeholders across surgical specialties.
  • Connect with clinical and non-clinical stakeholders, including theatre and procurement teams.
  • Build close relationships with field-based Sales Specialists and support the coordination of digital communication across territories.
  • Build relationships with national and strategic partners across the NHS and private sectors, providing updates on product supply, backorders, and code queries.
  • Lead the customer base through business-plan development, servicing existing customers, and identifying opportunities to upgrade customers to clinically appropriate alternatives.
  • Share key external-marketplace insights internally to inform future business plans.
  • Maintain competence in focus areas and promote the product portfolio.
  • Analyze account strategies and plans using key systems and data to understand the business environment and account needs.
  • Develop, deploy, and maintain tactical account-level plans aligned with business and customer objectives.
  • Plan customer activity to deliver account plans and breakthroughs.
  • Build a network of customer relationships through remote technology to support customers day to day and maximize opportunities to sell the value of the Wound Closure & Healing portfolio and services.
  • Proactively schedule regular virtual calls with key customers to provide updates, education opportunities, and support in understanding issues and identifying solutions.
  • Use remote-selling assets to present brand value propositions and customer solutions that positively influence buying behavior.
  • Deploy digital assets, including email and web-based content, to maximize reach and engagement.
  • Use social media to create an effective network and engage directly with customers.
  • Understand technical information relevant to the Wound Closure & Healing portfolio.
  • Maintain up-to-date market and industry knowledge.
  • Work collaboratively with Sales Specialists, Marketing, Professional Education, and other Commercial teams to manage the business.
Desired Qualifications
  • Experience selling virtually is strongly preferred.
  • Experience in medical device sales within Wound Closure is preferred.
  • Preferred skills include business behavior, Customer Effort Score, execution focus, goal attainment, innovation, market expansion, market research, product knowledge, and solutions selling.

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Remote Work Options
  • Performance Bonus

Growth & Insights and Company News

6 month growth

6%

1 year growth

-2%

2 year growth

-2%
Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 23rd, 2026
Smith & Nephew's $22B talks to buy J&J's orthopaedics unit collapse over who would lead

Smith & Nephew's merger talks with Johnson & Johnson (J&J) over its orthopaedics unit collapsed over who would lead the combined company, the Financial Times reported. The sides had reportedly agreed on the main financial terms and the deal structure. J&J wanted Namal Nawana, who runs its orthopaedics unit and formerly led Smith & Nephew, to lead the business. Smith & Nephew wanted current chief executive officer Deepak Nath to stay. Smith & Nephew's offer valued J&J's hip and knee unit at up to $22 billion, almost double its own market value. J&J shareholders would have owned 50.1% of the combined company. J&J is leaning toward spinning off the unit as DePuy Synthes, targeting mid-2027. Reuters reported the unit sought around $20 billion and drew private equity interest. Both companies declined to comment.

Yahoo Finance
Oct 23rd, 2026
ETFs sell $54.1M of Johnson & Johnson, extending two-day selling streak

ETFs sold a net $54.1 million of Johnson & Johnson (JNJ) shares on Wednesday, extending a two-day run of net selling. Twenty-five funds cut their holdings, 24 added shares, and 153 held steady. The Health Care Select Sector SPDR (XLV) led the selling, cutting 153,134 shares worth $39.5 million. The iShares Core S&P 500 ETF (IVV) sold $11.5 million, and the iShares MSCI USA Momentum Factor ETF (MTUM) sold $5.4 million. Tuesday saw net selling of $20.0 million, after net buying of $38.1 million on Monday and $84.4 million on October 16. JNJ has a market cap of $644.9 billion and has returned 31.39% year to date.

Yahoo Finance
Oct 22nd, 2026
JNJ rated buy with $289 target as pharma growth of 8% outpaces MedTech's 2.5%

Johnson & Johnson (JNJ) earns a "buy" rating from 24/7 Wall St., with a 12-month price target of $288.66. That implies 11.48% upside from the $258.93 close on October 20. Growth is coming from pharma. Innovative Medicine sales rose 7.9% last quarter, while MedTech grew 2.5%. The analyst says the stock hinges on whether devices can close that gap. Third-quarter sales reached $25.4 billion. Adjusted earnings per share (EPS) were $2.59, but GAAP EPS fell to $0.09 after about $7 billion of charges, mostly tied to a proposed talc settlement and two deals. Management cut adjusted EPS guidance to $11.05 to $11.15. The bull case is $302.93, or 17% upside. Tremfya grew 68%, and management expects it to become a $10 billion-plus franchise.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.